Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:


Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Generic Companies with Tentative Approvals for: Mylan Pharma

See Plans and Pricing

« Back to Dashboard

Mylan Pharma Generic Filers with Tentative Approvals

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Applicant Generic Name NDA Strength Dosage Form
Mylan Pharma rasagiline mesylate 201971 1MG TABLET; ORAL
Mylan Pharma rosiglitazone maleate 078825 8MG TABLET; ORAL
Mylan Pharma lopinavir; ritonavir 091202 200MG; 50MG TABLET; ORAL
Mylan Pharma levofloxacin 090063 500MG TABLET; ORAL
Mylan Pharma ezetimibe; simvastatin 200082 10MG; 40MG TABLET; ORAL
Mylan Pharma sildenafil citrate 201171 25MG TABLET; ORAL
>Applicant >Generic Name >NDA >Strength >Dosage Form

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.